We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01624753
First Posted: June 21, 2012
Last Update Posted: November 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Singapore General Hospital
  Purpose

Fibered confocal fluorescence microscopy (FCFM) (CellvizioR Lung, MaunaKea Technologies, France) could potentially provide diagnostic information on fibrosis and inflammation of the distal air spaces associated with diffuse parenchymal lung diseases without the need for lung biopsies, thereby fulfilling the gap in the investigators current medical practice of a minimally invasive procedures with few complications and a high diagnostic fidelity.

In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent FCFM imaging to be performed during the bronchoscopic procedure. The investigators aim to identify and catalogue distinct and discriminating features seen on images obtained from fibered confocal fluorescence microscopy in this group of patients, and to correlate these findings with specific high resolution computed tomography (HRCT) features and pathological findings if available. Eventually the investigators hope to create diagnostic criteria for fibered confocal fluorescence microscopy image interpretation of specific diffuse parenchymal lung disease entities.


Condition Intervention
Diffuse Parenchymal Lung Diseases Device: confocal microscopy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases

Resource links provided by NLM:


Further study details as provided by Singapore General Hospital:

Primary Outcome Measures:
  • Univariate and multivariate logistic regression analysis of the FCFM image features identified to discriminate against HRCT features and pathology. [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Utilize receiver operating characteristic (ROC) curves to identify the FCFM image feature or combination of features which demonstrates the best sensitivity and specificity for each HRCT feature and pathology. [ Time Frame: 5 years ]
  • Comparison of the areas under the curves for the interpretation of 2 still FCFM image frames of the same sequence recording of a single alveolar segment. [ Time Frame: 5 years ]
  • Using Kappa values to quantify a high study agreement (kappa >0.8) between the assessors and within an assessor for FCFM image interpretation. [ Time Frame: 5 years ]
  • Complication rate of fibered confocal fluorescence microscopy over and above standard bronchoscopy. [ Time Frame: 5 years ]

Enrollment: 27
Study Start Date: May 2012
Study Completion Date: November 2017
Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: confocal microscopy
During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
Device: confocal microscopy
During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
Other Names:
  • Fibered confocal fluorescence microscopy imaging
  • alveoloscopy
  • Alveoflex Confocal MiniprobeTM

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients 21 years old and older diagnosed with suspected diffuse parenchymal lung disease (multi-lobar pulmonary infiltrates)
  2. Patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup
  3. Ability and willingness to sign informed consent

Exclusion Criteria:

  1. Contraindications to bronchoscopic evaluation eg. Haemodynamic instability, respiratory failure, uncorrected coagulopathy
  2. Suspected/confirmed pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01624753


Locations
Singapore
Singapore General Hospital
Singapore, Singapore, 169608
Sponsors and Collaborators
Singapore General Hospital
Investigators
Principal Investigator: Su Ying Low, BMBCh Singapore General Hospital
  More Information

Publications:
Responsible Party: Singapore General Hospital
ClinicalTrials.gov Identifier: NCT01624753     History of Changes
Other Study ID Numbers: 2012/245/Cfcfm
First Submitted: May 15, 2012
First Posted: June 21, 2012
Last Update Posted: November 8, 2017
Last Verified: November 2017

Keywords provided by Singapore General Hospital:
interstitial lung disease
interstitial pneumonia
idiopathic pulmonary fibrosis

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases